Joseph Monahan - 31 Dec 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Scientific Officer
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
31 Dec 2024
Net transactions value
$0
Form type
4
Filing time
03 Jan 2025, 18:25:12 UTC
Previous filing
12 Dec 2024
Next filing
04 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +73,750 +43% 245,533 31 Dec 2024 Direct F1
transaction ACRS Common Stock Tax liability -32,937 -13% 212,596 31 Dec 2024 Direct F1, F2
transaction ACRS Common Stock Options Exercise +17,380 +8.2% 229,976 02 Jan 2025 Direct F1
transaction ACRS Common Stock Tax liability -8,914 -3.9% 221,062 02 Jan 2025 Direct F1, F2
holding ACRS Common Stock 193 31 Dec 2024 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -73,750 -50% $0.000000 73,750 31 Dec 2024 Common Stock 73,750 Direct F1, F3
transaction ACRS Restricted Stock Units Award $0 +52,667 $0.000000 52,667 02 Jan 2025 Common Stock 52,667 Direct F1, F4
transaction ACRS Restricted Stock Units Options Exercise $0 -17,380 -33% $0.000000 35,287 02 Jan 2025 Common Stock 17,380 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2 The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3 50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F4 The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.